Additional findings in this case also occasionally reported in the RTK1 subgroup include TP53 mutation, loss of 10q, and homozygous deletion of CDKN2A/B, though these findings are nonspecific and common in many high‐grade gliomas. This evidence concerns the gene CDKN2A and central nervous system cancer.